In addition to the clinical studies summarized in Table 2 for PPARγ agonists, a dual PPARδ/PPARγ agonist currently is being evaluated for its effects on the risk of developing dementia in subjects with mild to moderate AD. Here, PPARG is linked to Alzheimer disease.